Aim and Scope of the Journal
2016 Impact Factor: 0.495
5-year Impact Factor: 0.425
© 2017 Clarivate Analytics, Journal Citation Reports ®
Psychiatry and Clinical Psychopharmacology (PCP) aims to reach a national and international audience and will accept submissions from authors worldwide. It gives high priority to original studies of interest to clinicians and scientists in applied and basic neurosciences and related disciplines. Psychiatry and Clinical Psychopharmacology publishes high quality research targeted to specialists, residents and scientists in psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related sciences.
Topics of current interest to clinical, experimental and basic scientists are published in critical subjects, such as psychopharmacology, psychiatry and behavioral science. Psychiatry and Clinical Psychopharmacology effectively bridges the gap between basic science and clinical application. Access to the Journal is available to all interested persons with no subscription fees, furthering the aim of reaching all interested national and international associations and individuals.
Psychiatry and Clinical Psychopharmacology was formerly titled Bulletin of Clinical Psychopharmacology from the first volume in 1990 until 2016. From January 2017 and on, Psychiatry and Clinical Psychopharmacology has been published by Taylor & Francis Group.
The standard article publishing charge (APC) for this journal is £575 / US$750 / €665. Depending on your location these charges may be subject to local taxes. Part of our agreement with Taylor & Francis Group, during the first 3 yearsd (2017, 2018, and 2019), the manuscripts from Turkish colleagues will be published free of charge supported by a Publishing Grant from the Turkish Association for Psychopharmacology.